Working… Menu

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04963413
Recruitment Status : Not yet recruiting
First Posted : July 15, 2021
Last Update Posted : August 4, 2021
Immunomic Therapeutics, Inc.
Information provided by (Responsible Party):
University of Florida

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2025